Given the evidence that cells overcome KRAS codon bias by upregulating translation (Fig. 5), we hypothesized that inhibitors of translation may be selectively potent in CRC cells with acquired KRASG12 or KRASG13 site mutations, thereby revealing a synthetic lethality of the resistant state and a potential target in anti-EGFR resistant disease. Here, KRAS is linked to colorectal carcinoma.